Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacubitril/valsartan versus enalapril for physical activity and 6-minute walk performance in adults with chronic HFrEF
2016-003085-32Phase 3Completed
- Sponsor
- Novartis
- Start
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in heart failure with reduced ejection fraction (HFrEF) and chronic heart failure (CHF) comparing Sacubitril/valsartan arm with Enalapril arm (2 arms). Primary endpoint: Change from baseline in 6-minute walking test. Started Sep 2016; status: completed.
02
Drugs
sacubitril + valsartanenalapril
03
Conditions
heart failure with reduced ejection fraction (HFrEF)chronic heart failure (CHF)
Beyond the preview
Go deeper on 2016-003085-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003085-32.